Valley Diagnostics and Aberystwyth University announce license agreements to commercialize innovative diagnostic tests
Valley Diagnostics has signed several licensing agreements with its research partner and collaborator Aberystwyth University to bring to market innovative diagnostic tests aimed at revolutionizing disease detection.
The agreements grant Valley Diagnostics exclusive global rights to patented-protected biomarkers in four application areas including prostate cancer, lung cancer, bovine tuberculosis (bTB), and paratuberculosis (paraTB), also known as Johne’s disease.
Under the terms of the agreement, Valley Diagnostics will leverage its knowledge and expertise in commercializing healthcare products and digital technology to commercialize LFTs that can identify human and animal disease biomarkers, allowing for early detection and diagnosis of diseases. The partnership is expected to significantly change the diagnostic testing market especially in prostate cancer.
Valley Diagnostics is working to develop a test method that can identify a range of disease-causing biomarkers from a single sample of urine. The company's innovative biomarker fingerprint lateral flow approach offers a simple, easy-to-use, and inexpensive way to diagnose diseases with up to 95% accuracy, according to on-file data.
The agreement is effective immediately.
